Header AG Spuler

Spuler Lab



We take our muscles for granted. They permit us to go about our daily lives and with perhaps the exception of a few aches and pains they serve us well until our lives have ended.

However, for persons with genetic muscle diseases, this happy state-of-affairs is not the case.

These persons are wheel chair bound from child- or young adulthood until they die. There are many such patients. Genetic muscle diseases are not rare. But acquired muscle diseases such as critical care myopathy, muscle cachexia following cancer, heart failure or renal failure, traumatic muscle ischemia, or myopathy following drug reactions are definitely even more common.

We still have no treatment for any genetic muscle disease. However, we have made marked progress on an understanding of their pathologies. For acquired muscle disease, we are in the process of developing treatment strategies, although as always, “vigilance equals avoidance”.


Group Leader

Prof. Dr. Simone Spuler


Phone +49 30 450 540501 and 450 540504


Administrative Coordinator

Susanne Wissler


Phone +49 30 450 540504

Administrative Coordinator of the Research Group "Muscle Sciences and University Outpatient Clinic for Muscle Disorders" and the International Research Training Group for Myology (MyoGrad) since 2010


Senior Scientist

Dr. Andreas Marg

Phone +49 30 450 540524

Postdoctoral fellow since 2011 and senior scientist of the group
Involved in the project “
Satellite cells and heterogeneity


Science Translation

Biniam Bekele

biniam. bekele@charite.de
Phone +49 30 450 540518
Research fellow and physician 
Involved in the project "Muscle stem cells as ATMP"

Janine Kieshauer, M. Sc.

Phone +49 30 450 540518
Member of research staff since 2017

Involved in the project: "Validation of processing and manufacturing human muscle stem cells as an ATMP" 

Dr. Verena Schöwel, MD, MBA

Phone +49 30 450 540523
Research fellow and physician in the outpatient clinic for muscular disorders 2012-2014
Fellow of the Clinician Scientist Program of Charité and MDC (KAP) 2010-2012
Clinical and Research Fellow, GEROK Fellowship (KFO192) 2008-2009
Involved in the project "Muscle stem cells as ATMP - Building a Biobank"

Outpatient Clinic

Elisabetta Gazzerro, MD

Phone +49 30 450 540514

Clinician scientist and responsible for the outpatient clinic for muscular disorders
Involved in the project “Immunological impact of muscular dystrophies”



Dr. Helena Escobar Fernandez

Phone +49 30 450 540523

MyoGrad PhD fellowship from 2011-2015 and postdoctoral fellow since 2016
Involved in the project “Precise gene editing of muscular dystrophy-causing mutations in patient-derived induced pluripotent stem cells”


Dr. Jakub Malcher

Phone +49 30 450 540518
MyoGrad PhD fellowship from 2013-2018 and postdoctoral fellow since 2018

Involved in the project “Exon skipping and genome editing as therapeutic strategies in dysferlinopathy”

Dr. Eric Metzler

Phone +49 30 450 540523
PhD fellowship from  2015-2019 and postdoctoral fellow since 2019

Involved in the project “Primary and induced pluripotent stem cell-derived human satellite cells for cell-based therapies”

Dr. Stefanie Müthel

Phone +49 30 450 540518

Postdoctoral fellow since 2018
Involved in the project "Precise gene editing of LGMD2A causing mutations"


Dr. Hans-Jürgen Peter

Phone +49 30 450 540584

Postdoctoral fellow since 2018
Involved in the project “Production of bacterial nanocellulose”

Dr. Joanna Schneider (0,5 Position, parental leave)

Phone +49 30 450 540514

Research fellow and physician in the outpatient clinic for muscular disorders 2004-2013
Fellow of the Clinician Scientist Program of the Charité and MDC since 2016
Involved in the project “Epigenetic changes in critical illness myopathy”


Doctoral students

Silvia Di Francescantonio, M. Sc. Medical Biology

Phone +49 30 450 540506  

PhD student (MyoGrad PhD fellowship) since January 2017
Involved in the project “Developing of a human muscle stem cell culture strategy to investigate the maintenance of stem cell quiescence”


Alexej Zhogov, Medical student

Phone +49 30 450 540518
Medical student since January 2019

Involved in the project “Characterization of humanized mouse models for muscular dystrophy"

Technical Assistents

Stephanie Meyer-Liesener (Head Technician)

Phone +49 30 450 540506


Stefanie Haafke 

Phone +49 30 450 540518


Adrienne Rothe

Phone +49 30 450 540518




Gene Editing in Muscular Dystrophies

Involved people: Helena Escobar, Jakub Malcher; Stefanie Müthel, Alexej Zhogov

Precise gene editing of muscular dystrophy-causing mutations in patient-derived induced pluripotent stem cells

Helena Escobar

Muscular dystrophies are devastating diseases for which specific treatments are still lacking. They cause a progressive loss, degeneration and weakness of skeletal muscle and are often monogenic (caused by mutations in a single gene). A possible therapeutic avenue is thus to repair the genetic defect in patient-derived cells and later use those for autologous transplantation. Muscle stem cells (MSC) are responsible for muscle regeneration and would be the cell type of choice for repairing dystrophic muscles in a cell therapy context. However, they are scarce within the muscle tissue, have a limited proliferative potential and are difficult to manipulate genetically. Therefore, the number of MSC that could be taken from a patient and re-infused following gene repair would likely not suffice to treat large groups of muscles. Induced pluripotent stem cells (iPSC), on the other hand, can be generated from the patient’s adult somatic cells, widely expanded ex vivo, genetically corrected and differentiated back into cells displaying some of the characteristics of MSC. Our work focuses on developing a platform for precise gene editing of muscular dystrophy-causing mutations in patient-derived iPSC and the subsequent generation of gene-corrected MSC-like cells from each individual donor. We are developing methods to reliably assess the phenotypic rescue of the genetic defect in vitro as well as the biosafety features and in vivo regenerative potential of the gene-corrected iPSC-derived MSC through transplantation studies into mouse skeletal muscle.

Exon skipping and genome editing as therapeutic strategies in dysferlinopathy

Jakub Malcher

Limb-girdle muscular dystrophy type 2B (LGMD2B) is characterised by progressive muscle wasting that starts manifesting in young adults and progresses throughout their whole life. It is caused by mutations in the dysferlin gene that lead to the formation of misfolded dysferlin proteins affecting the muscle repair process. Using a new knock-in mouse carrying a missense mutation in one of the exons, gene therapy strategies including exon skipping and genome editing are studied. The project aim is to design appropriate antisense sequences that will be capable of removing the exon of interest and form a truncated but functional version of dysferlin. The feasibility of exon skipping is assessed using an in vitro model and the laser wounding assay. We are investigating the therapeutic efficacy both in vitro and in vivo. During the project, we also study possibilities of permanent mutation repair by means of currently available genome editing techniques.

Precise gene editing of LGMD2A causing mutations

Stefanie Müthel


Muscle Stem Cells

Involved people: Silvia Di Francescantonio, Andreas Marg, Eric Metzler

Developing of a human muscle stem cell culture strategy to investigate the maintenance of stem cell quiescence

Silvia Di Francescantonio


Satellite cells and heterogeneity

Andreas Marg

Muscle repair and regeneration require activation of satellite cells. These rare muscle precursor cells are located in a specific niche and are probably mitotically quiescent in healthy muscle. It is unclear to what extent satellite cells are heterogeneous in respect to their gene expression profiles, their myogenic differentiation potential and their stemness. Today, our understanding of human satellite cell heterogeneity is fragmentary, but clinical applications of stem cell populations require extensive knowledge in this field.

In collaboration with the Berlin Institute for Medical Systems Biology (BIMSB), we use Drop-seq, a method that allows profiling of thousands of single cells by separating them in tiny droplets with barcoded primer beads. After sequencing, we get the mRNA expression profiles from thousands of satellite cells. This is a significant step for a better understanding of these fascinating cells.

Reprogramming and redifferentiation of human muscle stem cells into induced pluripotent stem cells

Eric Metzler

The development of cell-based therapies represents a keystone in the research aiming for the treatment of muscular dystrophies. Therefore, one part of this work aims to develop promising culture techniques for primary human biopsy-derived satellite cells to improve the outcome of engraftment experiments.

Unfortunately, primary satellite cells will hardly become available in the required high numbers. Instead, human induced pluripotent stem cells (iPSCs) represent the key to unrestricted cell numbers necessary for gene correction and repopulation of large muscles for therapeutic purposes without evoking an immune response. Thus, another major part of this work aims to establish the differentiation of human iPSCs towards the myogenic lineage by recently published protocols.

Toxic Myopathies

Involved people: Joanna Schneider

Epigenetic changes and repair of the DNA breaks in skeletal muscle/or muscle stem cells in critical illness myopathy

Joanna Schneider

Critical illness myopathy (CIM) is a devastating acquired skeletal muscle disease characterized by atrophy, flaccid paralysis and respiratory failure. It develops in severely ill patients during the course of critical illness and is a frequent complication of intensive care unit (ICU) treatment. It is a very peculiar aspect of CIM that, in some patients, skeletal muscle atrophy and weakness last for a prolonged period of time, often lifelong, although all identified risk factors like inflammation, hyperglycemia, medications etc. have been removed. We hypothesize that the acute phase of severe critical illness leads to epigenetic changes in skeletal muscle stem cells or early myoblasts, which results in an impaired ability of muscles to regenerate, a long lasting myopathy and an increase of DNA double-strand breaks in the muscle cells. Our project aims to identify and characterize the epigenetic modifications in muscle stem cells derived from acute-onset CIM patients within the first days after admission to the ICU. We analyze the epigenome and transcriptome as well as the DNA double-strand breaks process of activated satellite cells and early myoblasts. This project is part of the Clinical Scientist Program of the Berlin Institute of Health and Charité - Universitätsmedizin Berlin.

Application oriented projects

Involved people: Biniam Bekele, Janine Kieshauer, Hans-Jürgen Peter, Verena Schöwel

Validation of processing and manufacturing human muscle stem cells as an ATMP

Janine Kieshauer


Production of bacterial nanocellulose

Hans-Jürgen Peter


Muscle stem cells as ATMP - Creation of a biobank

Verena Schöwel


Clinical Research

Involved people: Michael Boschmann, Elisabetta Gazzerro, Jeanette Schulz-Menger

  • International clinical trial on the natural history of dysferlinopathies
  • Muscle metabolism in facioscapulohumeral muscular dystrophy
  • Cardiac involvement in facioscapulohumeral muscular dystrophy




The university outpatient clinic for muscle disorders offers in close cooperation with primary care physicians or other specialists diagnostic expertise and long-term care for patients suffering from muscle diseases. Transferal is possible from all medical specialties.

Promotion of Young Scientists

MyoGrad is the first structured PhD training in muscle sciences worldwide. Highly qualified international PhD students complete a bi-nationally supervised thesis in the field of muscle-related cell and molecular biology or clinical aspects of muscle diseases.